Tebapivat clinical trials
Also written AG-946.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses tebapivat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses tebapivat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)Active, not recruitingPhase 2Agios Pharmaceuticals, Inc.NCT06924970Written as Tebapivat
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Active, not recruitingPhase 2Agios Pharmaceuticals, Inc.NCT05490446Written as Tebapivat
- A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy ParticipantsCompletedPhase 1Agios Pharmaceuticals, Inc.NCT06745271Written as [14C]-tebapivat
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell DiseaseCompletedPhase 1Agios Pharmaceuticals, Inc.NCT04536792Written as AG-946
Codes
What other systems call tebapivat · ClinicalTrials.gg INT017495
- UNII (FDA) ORG4KGP5ZSTEBAPIVATOne source FDA
- NCI Thesaurus C203234TebapivatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ORG4KGP5ZS | TEBAPIVAT | One source FDA |
| NCI Thesaurus | C203234 | Tebapivat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.